{
  "frames":[
    {
      "frame-id":"evem-PMC555773-UAZ-r1-19-3-1",
      "text":"iNOS is activated by interleukin-17",
      "arguments":[
        {
          "text":"iNOS",
          "argument-type":"entity",
          "object-type":"argument",
          "index":0,
          "argument-label":"controlled",
          "arg":"ment-PMC555773-UAZ-r1-19-3-113"
        },
        {
          "text":"interleukin-17",
          "argument-type":"entity",
          "object-type":"argument",
          "index":0,
          "argument-label":"controller",
          "arg":"ment-PMC555773-UAZ-r1-19-3-114"
        }
      ],
      "type":"activation",
      "frame-type":"event-mention",
      "subtype":"positive-activation",
      "end-pos":{
        "reference":"pass-PMC555773-UAZ-r1-19",
        "offset":446,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC555773-UAZ-r1-19",
        "offset":411,
        "object-type":"relative-pos"
      },
      "sentence":"sent-PMC555773-UAZ-r1-19-3",
      "found-by":"Positive_activation_syntax_2_verb",
      "object-meta":{
        "component":"REACH",
        "object-type":"meta-info"
      },
      "verbose-text":"Miljkovic and Trajkovic      have shown that iNOS is activated by interleukin-17 ( IL-17 ) , which is a proinflammatory T cell cytokine ."
    },
    {
      "frame-id":"evem-PMC555773-UAZ-r1-20-4-2",
      "text":"Endothelin-1 activates eNOS",
      "arguments":[
        {
          "text":"eNOS",
          "argument-type":"entity",
          "object-type":"argument",
          "index":0,
          "argument-label":"controlled",
          "arg":"ment-PMC555773-UAZ-r1-20-4-126"
        },
        {
          "text":"Endothelin-1",
          "argument-type":"entity",
          "object-type":"argument",
          "index":0,
          "argument-label":"controller",
          "arg":"ment-PMC555773-UAZ-r1-20-4-125"
        }
      ],
      "type":"activation",
      "frame-type":"event-mention",
      "subtype":"positive-activation",
      "end-pos":{
        "reference":"pass-PMC555773-UAZ-r1-20",
        "offset":780,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC555773-UAZ-r1-20",
        "offset":753,
        "object-type":"relative-pos"
      },
      "sentence":"sent-PMC555773-UAZ-r1-20-4",
      "found-by":"Positive_activation_syntax_1_verb",
      "object-meta":{
        "component":"REACH",
        "object-type":"meta-info"
      },
      "verbose-text":"Recently , Liu et al      have demonstrated that Endothelin-1 activates eNOS via heterotrimeric G protein beta-gamma subunit signaling to protein kinase B and Akt ."
    },
    {
      "frame-id":"evem-PMC555773-UAZ-r1-30-9-3",
      "text":"NO stimulates ADP",
      "arguments":[
        {
          "text":"ADP",
          "argument-type":"entity",
          "object-type":"argument",
          "index":0,
          "argument-label":"controlled",
          "arg":"ment-PMC555773-UAZ-r1-30-9-182"
        },
        {
          "text":"NO",
          "argument-type":"entity",
          "object-type":"argument",
          "index":0,
          "argument-label":"controller",
          "arg":"ment-PMC555773-UAZ-r1-30-9-181"
        }
      ],
      "type":"activation",
      "frame-type":"event-mention",
      "subtype":"positive-activation",
      "end-pos":{
        "reference":"pass-PMC555773-UAZ-r1-30",
        "offset":1374,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC555773-UAZ-r1-30",
        "offset":1357,
        "object-type":"relative-pos"
      },
      "sentence":"sent-PMC555773-UAZ-r1-30-9",
      "found-by":"Positive_activation_syntax_1_verb",
      "object-meta":{
        "component":"REACH",
        "object-type":"meta-info"
      },
      "verbose-text":"It has been observed that NO stimulates ADP ribosylation of many soluble and membrane bound proteins including G-proteins in vascular smooth muscles ."
    },
    {
      "frame-id":"evem-PMC555773-UAZ-r1-41-1-4",
      "text":"ACE produces angiotensin II",
      "arguments":[
        {
          "text":"angiotensin II",
          "argument-type":"entity",
          "object-type":"argument",
          "index":0,
          "argument-label":"controlled",
          "arg":"ment-PMC555773-UAZ-r1-41-1-277"
        },
        {
          "text":"ACE",
          "argument-type":"entity",
          "object-type":"argument",
          "index":0,
          "argument-label":"controller",
          "arg":"ment-PMC555773-UAZ-r1-41-1-276"
        }
      ],
      "type":"activation",
      "frame-type":"event-mention",
      "subtype":"positive-activation",
      "end-pos":{
        "reference":"pass-PMC555773-UAZ-r1-41",
        "offset":224,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC555773-UAZ-r1-41",
        "offset":197,
        "object-type":"relative-pos"
      },
      "sentence":"sent-PMC555773-UAZ-r1-41-1",
      "found-by":"Positive_activation_syntax_1_verb",
      "object-meta":{
        "component":"REACH",
        "object-type":"meta-info"
      },
      "verbose-text":"Since ACE produces angiotensin II in the heart , ACE inhibitors ( ACEIs ) may prevent coronary vasoconstriction and increase coronary blood flow ."
    },
    {
      "frame-id":"evem-PMC555773-UAZ-r1-41-0-5",
      "text":"Angiotensin converting enzyme (ACE) inhibitors inhibit the degradation of bradykinin",
      "arguments":[
        {
          "text":"bradykinin",
          "argument-type":"entity",
          "object-type":"argument",
          "index":0,
          "argument-label":"controlled",
          "arg":"ment-PMC555773-UAZ-r1-41-0-273"
        },
        {
          "text":"Angiotensin converting enzyme",
          "argument-type":"entity",
          "object-type":"argument",
          "index":0,
          "argument-label":"controller",
          "arg":"ment-PMC555773-UAZ-r1-41-0-271"
        }
      ],
      "type":"activation",
      "frame-type":"event-mention",
      "subtype":"negative-activation",
      "end-pos":{
        "reference":"pass-PMC555773-UAZ-r1-41",
        "offset":84,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC555773-UAZ-r1-41",
        "offset":0,
        "object-type":"relative-pos"
      },
      "sentence":"sent-PMC555773-UAZ-r1-41-0",
      "found-by":"Negative_activation_syntax_1_verb",
      "object-meta":{
        "component":"REACH",
        "object-type":"meta-info"
      },
      "verbose-text":"Angiotensin converting enzyme ( ACE ) inhibitors inhibit the degradation of bradykinin and contribute to accumulation of bradykinin and NO , both of which may be beneficial for diseased hearts ."
    },
    {
      "frame-id":"evem-PMC555773-UAZ-r1-41-0-6",
      "text":"ACE) inhibitors inhibit the degradation of bradykinin",
      "arguments":[
        {
          "text":"bradykinin",
          "argument-type":"entity",
          "object-type":"argument",
          "index":0,
          "argument-label":"controlled",
          "arg":"ment-PMC555773-UAZ-r1-41-0-273"
        },
        {
          "text":"ACE",
          "argument-type":"entity",
          "object-type":"argument",
          "index":0,
          "argument-label":"controller",
          "arg":"ment-PMC555773-UAZ-r1-41-0-272"
        }
      ],
      "type":"activation",
      "frame-type":"event-mention",
      "subtype":"negative-activation",
      "end-pos":{
        "reference":"pass-PMC555773-UAZ-r1-41",
        "offset":84,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC555773-UAZ-r1-41",
        "offset":31,
        "object-type":"relative-pos"
      },
      "sentence":"sent-PMC555773-UAZ-r1-41-0",
      "found-by":"Negative_activation_syntax_1_verb",
      "object-meta":{
        "component":"REACH",
        "object-type":"meta-info"
      },
      "verbose-text":"Angiotensin converting enzyme ( ACE ) inhibitors inhibit the degradation of bradykinin and contribute to accumulation of bradykinin and NO , both of which may be beneficial for diseased hearts ."
    },
    {
      "frame-id":"evem-PMC555773-UAZ-r1-41-2-7",
      "text":"ACEIs may increase cardiac NO",
      "arguments":[
        {
          "text":"cardiac NO",
          "argument-type":"entity",
          "object-type":"argument",
          "index":0,
          "argument-label":"controlled",
          "arg":"ment-PMC555773-UAZ-r1-41-2-282"
        },
        {
          "text":"ACEIs",
          "argument-type":"entity",
          "object-type":"argument",
          "index":0,
          "argument-label":"controller",
          "arg":"ment-PMC555773-UAZ-r1-41-2-281"
        }
      ],
      "type":"activation",
      "frame-type":"event-mention",
      "subtype":"positive-activation",
      "end-pos":{
        "reference":"pass-PMC555773-UAZ-r1-41",
        "offset":472,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC555773-UAZ-r1-41",
        "offset":443,
        "object-type":"relative-pos"
      },
      "sentence":"sent-PMC555773-UAZ-r1-41-2",
      "found-by":"Positive_activation_syntax_1_verb",
      "object-meta":{
        "component":"REACH",
        "object-type":"meta-info"
      },
      "verbose-text":"On the other hand , since ACEIs also inhibit kininase II , which results in reduced degradation of bradykinin , ACEIs may increase cardiac NO levels via stimulation of bradykinin receptors and the accumulation of bradykinin in the ischemic myocardium     ."
    },
    {
      "is-hypothesis":true,
      "frame-id":"evem-PMC555773-UAZ-r1-42-1-8",
      "text":"angiotensin II receptor antagonists can inhibit the effects of angiotensin II",
      "arguments":[
        {
          "text":"angiotensin II",
          "argument-type":"entity",
          "object-type":"argument",
          "index":0,
          "argument-label":"controlled",
          "arg":"ment-PMC555773-UAZ-r1-42-1-288"
        },
        {
          "text":"angiotensin II receptor",
          "argument-type":"entity",
          "object-type":"argument",
          "index":0,
          "argument-label":"controller",
          "arg":"ment-PMC555773-UAZ-r1-42-1-287"
        }
      ],
      "type":"activation",
      "frame-type":"event-mention",
      "subtype":"negative-activation",
      "end-pos":{
        "reference":"pass-PMC555773-UAZ-r1-42",
        "offset":274,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC555773-UAZ-r1-42",
        "offset":197,
        "object-type":"relative-pos"
      },
      "sentence":"sent-PMC555773-UAZ-r1-42-1",
      "found-by":"Negative_activation_syntax_1_verb",
      "object-meta":{
        "component":"REACH",
        "object-type":"meta-info"
      },
      "verbose-text":"Since angiotensin II receptor antagonists can inhibit the effects of angiotensin II via ACE independent pathways , for example , chymase , they were considered to be more effective than ACEIs ."
    },
    {
      "frame-id":"evem-PMC555773-UAZ-r1-48-8-9",
      "text":"Angiotensin II also stimulates the production of endothelin",
      "arguments":[
        {
          "text":"endothelin",
          "argument-type":"entity",
          "object-type":"argument",
          "index":0,
          "argument-label":"controlled",
          "arg":"ment-PMC555773-UAZ-r1-48-8-340"
        },
        {
          "text":"Angiotensin II",
          "argument-type":"entity",
          "object-type":"argument",
          "index":0,
          "argument-label":"controller",
          "arg":"ment-PMC555773-UAZ-r1-48-8-339"
        }
      ],
      "type":"activation",
      "frame-type":"event-mention",
      "subtype":"positive-activation",
      "end-pos":{
        "reference":"pass-PMC555773-UAZ-r1-48",
        "offset":785,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC555773-UAZ-r1-48",
        "offset":726,
        "object-type":"relative-pos"
      },
      "sentence":"sent-PMC555773-UAZ-r1-48-8",
      "found-by":"Positive_activation_syntax_1_verb",
      "object-meta":{
        "component":"REACH",
        "object-type":"meta-info"
      },
      "verbose-text":"Angiotensin II also stimulates the production of endothelin and TGF-beta ."
    },
    {
      "frame-id":"evem-PMC555773-UAZ-r1-48-8-10",
      "text":"Angiotensin II also stimulates the production of endothelin and TGF-beta",
      "arguments":[
        {
          "text":"TGF-beta",
          "argument-type":"entity",
          "object-type":"argument",
          "index":0,
          "argument-label":"controlled",
          "arg":"ment-PMC555773-UAZ-r1-48-8-341"
        },
        {
          "text":"Angiotensin II",
          "argument-type":"entity",
          "object-type":"argument",
          "index":0,
          "argument-label":"controller",
          "arg":"ment-PMC555773-UAZ-r1-48-8-339"
        }
      ],
      "type":"activation",
      "frame-type":"event-mention",
      "subtype":"positive-activation",
      "end-pos":{
        "reference":"pass-PMC555773-UAZ-r1-48",
        "offset":798,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC555773-UAZ-r1-48",
        "offset":726,
        "object-type":"relative-pos"
      },
      "sentence":"sent-PMC555773-UAZ-r1-48-8",
      "found-by":"Positive_activation_syntax_1_verb",
      "object-meta":{
        "component":"REACH",
        "object-type":"meta-info"
      },
      "verbose-text":"Angiotensin II also stimulates the production of endothelin and TGF-beta ."
    },
    {
      "frame-id":"evem-PMC555773-UAZ-r1-48-14-11",
      "text":"LCPUFAs decreases insulin",
      "arguments":[
        {
          "text":"insulin",
          "argument-type":"entity",
          "object-type":"argument",
          "index":0,
          "argument-label":"controlled",
          "arg":"ment-PMC555773-UAZ-r1-48-14-354"
        },
        {
          "text":"LCPUFAs",
          "argument-type":"entity",
          "object-type":"argument",
          "index":0,
          "argument-label":"controller",
          "arg":"ment-PMC555773-UAZ-r1-48-14-353"
        }
      ],
      "type":"activation",
      "frame-type":"event-mention",
      "subtype":"negative-activation",
      "end-pos":{
        "reference":"pass-PMC555773-UAZ-r1-48",
        "offset":1295,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC555773-UAZ-r1-48",
        "offset":1270,
        "object-type":"relative-pos"
      },
      "sentence":"sent-PMC555773-UAZ-r1-48-14",
      "found-by":"Negative_activation_syntax_1_verb",
      "object-meta":{
        "component":"REACH",
        "object-type":"meta-info"
      },
      "verbose-text":"Prenatal supplementation of LCPUFAs decreases insulin resistance and prevents the development of hypertension in adult life , whereas deficiency of LCPUFAs in the prenatal period results in raised blood pressure later in life ."
    },
    {
      "frame-id":"evem-PMC555773-UAZ-r1-48-4-12",
      "text":"angiotensin II activate NAD(P)H",
      "arguments":[
        {
          "text":"NAD(P)H",
          "argument-type":"entity",
          "object-type":"argument",
          "index":0,
          "argument-label":"controlled",
          "arg":"ment-PMC555773-UAZ-r1-48-4-336"
        },
        {
          "text":"angiotensin II",
          "argument-type":"entity",
          "object-type":"argument",
          "index":0,
          "argument-label":"controller",
          "arg":"ment-PMC555773-UAZ-r1-48-4-335"
        }
      ],
      "type":"activation",
      "frame-type":"event-mention",
      "subtype":"positive-activation",
      "end-pos":{
        "reference":"pass-PMC555773-UAZ-r1-48",
        "offset":503,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC555773-UAZ-r1-48",
        "offset":472,
        "object-type":"relative-pos"
      },
      "sentence":"sent-PMC555773-UAZ-r1-48-4",
      "found-by":"Positive_activation_syntax_1_verb",
      "object-meta":{
        "component":"REACH",
        "object-type":"meta-info"
      },
      "verbose-text":"Physiological concentrations of angiotensin II activate NAD ( P ) H oxidase and trigger free radical generation ( especially that of O2 - . )"
    },
    {
      "frame-id":"evem-PMC555773-UAZ-r1-48-12-13",
      "text":"TGF-beta and enhance eNO",
      "arguments":[
        {
          "text":"eNO",
          "argument-type":"entity",
          "object-type":"argument",
          "index":0,
          "argument-label":"controlled",
          "arg":"ment-PMC555773-UAZ-r1-48-12-348"
        },
        {
          "text":"TGF-beta",
          "argument-type":"entity",
          "object-type":"argument",
          "index":0,
          "argument-label":"controller",
          "arg":"ment-PMC555773-UAZ-r1-48-12-347"
        }
      ],
      "type":"activation",
      "frame-type":"event-mention",
      "subtype":"positive-activation",
      "end-pos":{
        "reference":"pass-PMC555773-UAZ-r1-48",
        "offset":1070,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC555773-UAZ-r1-48",
        "offset":1046,
        "object-type":"relative-pos"
      },
      "sentence":"sent-PMC555773-UAZ-r1-48-12",
      "found-by":"Positive_activation_syntax_1_verb",
      "object-meta":{
        "component":"REACH",
        "object-type":"meta-info"
      },
      "verbose-text":"and TGF-beta and enhance eNO synthesis to bring about its beneficial actions ."
    },
    {
      "frame-id":"evem-PMC555773-UAZ-r1-50-3-14",
      "text":"production of cGMP by phosphodiesterases",
      "arguments":[
        {
          "text":"cGMP",
          "argument-type":"entity",
          "object-type":"argument",
          "index":0,
          "argument-label":"controlled",
          "arg":"ment-PMC555773-UAZ-r1-50-3-366"
        },
        {
          "text":"phosphodiesterases",
          "argument-type":"entity",
          "object-type":"argument",
          "index":0,
          "argument-label":"controller",
          "arg":"ment-PMC555773-UAZ-r1-50-3-367"
        }
      ],
      "type":"activation",
      "frame-type":"event-mention",
      "subtype":"positive-activation",
      "end-pos":{
        "reference":"pass-PMC555773-UAZ-r1-50",
        "offset":537,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC555773-UAZ-r1-50",
        "offset":497,
        "object-type":"relative-pos"
      },
      "sentence":"sent-PMC555773-UAZ-r1-50-3",
      "found-by":"Positive_activation_token_2_noun",
      "object-meta":{
        "component":"REACH",
        "object-type":"meta-info"
      },
      "verbose-text":"However , the NO pathway is modulated at multiple levels including transcription and expression of the NOS gene , regulation of the NOS activity , regulation of the production of cGMP by phosphodiesterases , postsynthetic oxidation of NO , and so forth ."
    }
  ],
  "object-type":"frame-collection",
  "object-meta":{
    "processing-end":"2015-06-14T21:48:34Z",
    "doc-id":"PMC555773",
    "component-type":"machine",
    "component":"REACH",
    "processing-start":"2015-06-14T21:46:19Z",
    "object-type":"meta-info",
    "organization":"UAZ"
  }
}
